Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://jh.elmerpub.com

Original Article

Volume 14, Number 1, February 2025, pages 14-19

Low Rate of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis

Figure

↓  Figure 1. Diffuse large B-cell lymphoma (DLBCL) cases and the patient inclusions and exclusions. CNS: central nervous system.
Figure 1.

Tables

↓  Table 1. Patients’ Characteristics
 
Characteristic Patients’ number %
CNS: central nervous system; IPI: international prognostic index; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Age (years), no (range) 56 16 - 87
Gender
  Male 58 57.50
  Female 43 42.50
Ann Arbor stage
  I 9 8.90
  II 21 20.80
  III 17 16.80
  IV 50 49.50
CNS-IPI score
  High-risk 25 24.75
  Intermediate-risk 44 43.50
  Low-risk 32 31.70
Chemotherapy
  R-CHOP 94 93
  Other 7 7.9
CNS relapse 2 2.0

 

↓  Table 2. Extranodal Sites Involved
 
Extranodal site Number %
GI: gastrointestinal.
Lung 27 26.00
Liver 20 19.80
Bone marrow 20 19.80
GI tract 9 8.90
Kidneys 5 4.95
Breast 4 3.96
Testis 2 2.00
Adrenal 2 2.00

 

↓  Table 3. Characteristics of 25 Patients With High-Risk CNS-IPI
 
Parameter Patients’ values, n (%)a
aNot otherwise specified. CNS: central nervous system; IPI: international prognostic index; IT: intrathecal.
Age (years), median (range) 65 (14 - 87)
Gender
  Male 16 (64)
  Female 9 (36)
Ann Arbor stage
  III 2 (8)
  IV 23 (92)
CNS-IPI score, n (%)
  4 11 (44)
  5 13 (52)
  6 1 (4)
Follow-up (months), median (range) 28 (4 - 114)
Patients alive at last follow-up 14 (56)
CNS prophylaxis
  Received 16 (64)
  Not received 9 (36)
Number of IT chemotherapy injections, median (range) 3 (1 - 6)